Nevro (NVRO)
(Delayed Data from NYSE)
$5.67 USD
+0.84 (17.39%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $5.67 0.00 (0.00%) 6:10 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
NVRO 5.67 +0.84(17.39%)
Will NVRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVRO
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
NVRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Why Is Nevro (NVRO) Down 8.8% Since Last Earnings Report?
Other News for NVRO
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nevro Corp (NVRO), Kymera Therapeutics (KYMR) and AbCellera Biologics (ABCL)
Assessing Nevro: Insights From 9 Financial Analysts
Nevro price target lowered by $4.50 at Truist, here's why
Nevro just upgraded at Wolfe Research, here's why
Hold Rating on Nevro Corp Amid Reduced Revenue Forecast and Market Uncertainty